Publications by authors named "M Stoler"
Introduction: Low-cost, accurate high-risk HPV tests are needed for cervical cancer screening in limited-resource settings.
Objective: To compare the performance of the low-cost Hybribio-H13 test with the Hybrid Capture® 2 to detect cervical intraepithelial neoplasia grade 2 or 3 (CIN2 and CIN3).
Materials And Methods: Archived baseline samples tested by the Hybrid Capture® 2 from women of the ASCUS-COL trial, aged 20 to 69 years, with biopsy-colposcopy directed diagnosis of CIN2+ (n = 143), CIN3+ (n = 51), and < CIN2 (n = 632) were blindly tested by the Hybribio-H13 test.
Objective: Transient receptor potential vanilloid 4 (TRPV4) is a nonselective cation channel important in many physiological and pathophysiological processes, including pulmonary disease. Using a murine model, we previously demonstrated that TRPV4 mediates lung ischemia-reperfusion injury, the major cause of primary graft dysfunction after transplant. The current study tests the hypothesis that treatment with a TRPV4 inhibitor will attenuate lung ischemia-reperfusion injury in a clinically relevant porcine lung transplant model.
View Article and Find Full Text PDFArticle Synopsis
- Active surveillance is increasingly being used instead of excisional treatment for younger women with cervical intraepithelial neoplasia grade 2 due to high regression rates and lower risk of preterm birth associated with surveillance.* -
- The study examined HPV type-specific persistence/progression in 455 women aged 23 to 40 who were diagnosed with cervical intraepithelial neoplasia grade 2 at Aarhus University Hospital between 2000 and 2010, highlighting the need for early identification of women at risk.* -
- Results indicated that over half (52.2%) of the participants exhibited persistent or progressive disease, emphasizing the importance of monitoring HPV types to assess risk during active surveillance.*
Background And Objectives: The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity study in 9- to 15-year-old boys and girls was extended to assess immunogenicity and effectiveness through 10 years after the last vaccine dose (NCT00943722).
Methods: Boys (n = 301) and girls (n = 971) who received three 9vHPV vaccine doses in the base study (day 1, months 2 and 6) enrolled in the extension. Serum was collected through month 126 for antibody assessments by competitive Luminex immunoassay and immunoglobulin G-Luminex immunoassay.
Cervical cancer is the fourth most common cancer worldwide, with over 600,000 new cases annually and approximately 350,000 cancer-related deaths per year. The disease burden is disproportionately distributed, with cancer-related mortality ranging from 5.2 deaths per 100,000 individuals in highly-developed countries, to 12.
View Article and Find Full Text PDF